Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
Status:
Completed
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 150 mg and 450 mg,
compared with placebo, as add-on to nasal spray standard-of-care (SoC), in reducing
endoscopic nasal polyp score in adult (≥ 18 years) patients with nasal polyposis and
concomitant asthma.